Felicia L. Wilson, M.D.
Pediatric Hematologist/OncologistProfessor of PediatricsSpecialty: Pediatrics, Cancer CareBoard Certifications
- American Board of Pediatrics (Pediatric Hematology-Oncology)
Education
- Medical School: Medical University of South Carolina College of Medicine | Charleston, SC
- Residency: Greenville Hospital System | Greenville, SC
- Fellowship: Emory University of Medicine | Atlanta, GA
Languages
- English
Locations
- Pediatric SpecialistsClinic is located in Strada Patient Care Center
Clinical Trials
AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Treatment for Germ Cell Tumor (GCT)
ARST1431 A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Treatment for Pediatric Oncology- Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
AALL1731 A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Treatment for Pediatric Oncology- Localized B-Lymphoblastic Lymphoma (B-LLy)
AALL1732 - A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Treatment for Pediatric Oncology- Newly Diagnosed High-Risk B-ALL
S1826 - A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Treatment for Pediatric Oncology - Classical Hodgkin Lymphoma
| ACNS1721: A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations |
Treatment for Pediatric Oncology - Brain tumor
ACNS1422-A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Treatment for Pediatric Oncology - Medulloblastoma
AAML1831 - A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Treatment for newly diagnoses myeloid leukemia